Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04585984 |
| Other study ID # |
1905-FIVI-063-NG |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
February 5, 2021 |
| Est. completion date |
May 2025 |
Study information
| Verified date |
March 2024 |
| Source |
Fundación IVI |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The quality of semen plays a fundamental role in correct fertilization and development of
normal embryos that result in a live birth. Unfortunately, semen quality has declined during
the last decades, and reduced more and more. The cases of male factor infertility currently
correspond to 30% of the reported cases of infertility. The parameters that are directly
affected in infertile men reflecting an impaired spermatogenesis are sperm concentration,
motility, morphology, ejaculate volume and DNA damage, in addition to various alterations at
the molecular level that often go unnoticed and are related to the physiological capacity of
the sperm. These alterations result in a decrease in reproductive capacity, which leads to
the need for assisted reproduction techniques (ART). The identification of new ways to
increase the quality of sperm could be very useful to improve the reproductive performance of
patients.
Probiotics are defined as 'living microorganisms, which, when administered in adequate
amounts, confer benefits for the health of the host'. The consumption of probiotics is
increasing worldwide as therapy for many different diseases and disorders. In the field of
assisted reproduction, the microbiome has been extensively studied with respect to the female
endometrium to assess endometrial receptivity. However, there is little evidence about the
role of the microbiome in semen. Previous studies demonstrated a moderate improvement on some
sperm parameters, but still there is a need to confirm its translation into a clinical
contribution to reproductive success.
The aim of this study is to evaluate the effect of these strains, Lactobacillus rhamnosus
CECT8361 and Bifidobacterium longum CECT7347, on the seminal quality of infertile patients
coming to IVIRMA clinics to undergo their first IVF/ICSI cycle by means of determining direct
improvement on the basic sperm analysis results, on sperm DNA integrity and on the seminal
microbiome profile, to ultimately evaluate the effect that it may have on the embryo quality
and reproductive results of the cycles of these patients.
Description:
This is a prospective randomized, unicentric, intervention study aimed at evaluating the
effect of the combination of two probiotics on seminal quality and subsequent reproductive
outcomes of infertile patients. As it is a food supplement, we will be subject to the
Biomedicine Regulation and not to the Clinical Trials Regulation, as already classified by
the Spanish Drug Agency. The study will be conducted on infertile patients at the IVIRMA
Valencia clinic for two years to complete planned interventions and data collection and
analysis. The reference population includes infertile patients coming to the clinic for
IVF/ICSI assisted reproduction treatment with own or donated oocytes.
Patients will come to the clinic to undergo the treatment. If their characteristics are in
accord with the inclusion criteria, the study will be presented and explained to them and
their partners so they can evaluate their participation in it. If they wish to participate,
they will sign an informed consent form, and they will be randomized using a
computer-generated randomisation list into the control group (who will receive placebo) or
the treatment group (who will receive the probiotic compound).
The success rate in patients with these characteristics, confirmed by the evaluation of
historical information from the clinic's own database, is approximately 35% of the cycles
using own oocytes, which can be used as a valid approximation. In a unilateral contrast test,
assuming a risk of an alpha error of 0.05 and a beta (statistical power) of 80%, to
demonstrate a difference of 15% thanks to the intervention, we need a number of 134 cases per
arm and, assuming losses of 5% during the follow-up, this number would be rounded to 140
cases per study group, which makes a total of 280 couples to be included in the study.
The trial is double-blind: the patient, the investigator and all site personnel (with the
exception of the trial nurse/coordinator and/or pharmacy assistant) will remain blinded
throughout the course of the trial as to which treatment each subject received, including the
assessing physician, the embryologist and other auxiliary members of the team.
The male assigned to the experimental group will start taking a 50% combination of the two
probiotics (Lactobacillus rhamnosus CECT8361 and Bifidobacterium longum CECT7347) at a dose
of 109 CFU/day on the same day of the first visit. The probiotics will be supplied by the
company ADM Biopolis S.L. (Valencia, Spain). The carrier of lyophilized probiotics is
maltodextrin and the mixture is encapsulated in hypromellose capsules. The patient will take
one capsule daily corresponding to the administration of 109 cfu/day. The patient should take
these probiotics for at least 21 days before undergoing an assisted reproduction cycle.
Patients receiving the placebo will be following the same instructions. For both groups of
patients, a seminal sample will be collected on their first visit to evaluate the baseline
quality of the semen, as well as a microbiome analysis will be carried out using 16S rRNA
sequencing (by ADM Biopolis) to determine the status of the semen at the starting point of
the study. After 21 days, the patients will be appointed to deposit a second semen sample in
order to perform the IVF/ICSI cycle. This sample will also be analysed, both for semen
parameters and microbiome. Values obtained from both of the samples collected will be
compared to observe the effect of the administration of the probiotic on the quality of sperm
and its microbial population.
Fresh semen samples will be evaluated by means of a spermiogram following the standard
operating procedures, in which data will be collected on volume, pH, sperm concentration,
sperm mobility, cell viability and morphology. In addition, a DNA fragmentation analysis will
be carried out using the Halosperm G2 kit (Halotech) based on the sperm chromatin dispersion
technique. A part of the fresh sample will be frozen by submersion into liquid nitrogen and
then storage in a -80ºC freezer, and sent to ADM Biopolis to perform the taxonomical
identification of the bacterial populations in the semen samples using 16S rRNA sequencing
with the Ion Torrent platform (Lifetechnologies).
Once the IVF/ICSI has been performed and oocytes have been correctly fertilised, embryo
selection and blastocyst transfer will be carried out according to the usual medical practice
to the woman's uterus, so that they can continue their development in the womb.
During recruitment, the couple will also sign a consent form allowing the team to collect
data from the results of the cycle, both during embryo development and during the pregnancy
and the delivery.
A database will be defined with the variables destined to be analysed according to the
objectives set: semen quality analysis, sperm DNA fragmentation, microbial analysis, embryo
development, gestation and delivery. The exported data will be duly codified in order to
protect the clinical and personal information of the patients according to the Spanish data
protection law. Finally, and prior to the statistical study, an exploratory data analysis
will be carried out to review the quality of the information extracted.
The main variable of the study is the live birth rate per cycle defined as the percentage of
cases in which a complete treatment of assisted reproduction is carried out with control or
experimental semen, which manage to obtain offspring for each cycle of ovarian stimulation
included in the study.
